State of New Jersey Common Pension Fund D Acquires New Shares in Dyne Therapeutics, Inc. $DYN

State of New Jersey Common Pension Fund D acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,562 shares of the company’s stock, valued at approximately $617,000.

Several other hedge funds have also recently bought and sold shares of DYN. Chung Wu Investment Group LLC bought a new position in Dyne Therapeutics during the third quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares during the last quarter. Arkadios Wealth Advisors bought a new position in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $128,000. Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Dyne Therapeutics by 1,006.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,499 shares of the company’s stock worth $205,000 after purchasing an additional 9,550 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Up 4.8%

DYN opened at $18.46 on Tuesday. The business has a 50 day moving average of $18.12 and a 200-day moving average of $18.60. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of -5.21 and a beta of 1.08. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business posted ($1.05) EPS. As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the transaction, the director owned 7,962 shares in the company, valued at approximately $144,749.16. The trade was a 91.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,552,911 shares of company stock valued at $29,694,469. Company insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on DYN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Morgan Stanley reduced their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.14.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.